Healthcare Simulation in Higher Education

Avispl

The Center for Digital Education (CDE) hosted “Future-Ready Learning: How Technology and Simulation Are Transforming Healthcare Education.” This webinar looked at the ways that healthcare simulation solutions are being applied to give competitive advantage to the colleges, universities and teaching hospitals that adopt them.
Watch Now

Spotlight

Discover how Futurism AI is revolutionizing the healthcare industry with cutting-edge AI and Machine Learning technologies. Delve into how we leverage AI to predict and prevent equipment failures, monitor disease outbreaks, expedite clinical trials, detect fraudulent activity, and pioneer drug development.

OTHER ON-DEMAND WEBINARS

Medicare Advantage technology trends to improve growth and star ratings via PBP, ANOC, EOC, and SB automation

Growth opportunities for payers in different segments and regions. The competitive state of the Medicare Advantage market heading into 2022.
Watch Now

Elevating Your Approach to Patient Communications

Change Healthcare

In this on-demand webinar, we take a closer look at two key trends currently reshaping our industry: consumerism and digitization. We’ll discuss how providers can capitalize on these trends to simultaneously improve patient satisfaction and cash flow.
Watch Now

Are You Ready for EKRA? What You Need to Know Now About How this New Legislation Affects Your Lab

darkdaily

As written, however, EKRA is far more expansive with its broad language enabling the federal government to monitor provider arrangements intended to generate business for any laboratory services, not just those related to individuals in treatment for substance abuse disorders, payable by a FHCP or commercial health insurer.
Watch Now

Immunotherapy Advances in Small Cell Lung Cancer

Cancerresearch

Small cell lung cancer (SCLC) is aggressive and often difficult to treat, but many patients may have new hope. On August 17, 2018, the FDA approved the first immunotherapy the checkpoint inhibitor nivolumab (Opdivo, Bristol-Myers Squibb for patients with small cell lung cancer. Since this approval, there has been renewed focus on how to make different immunotherapies work for a disease which typicallly comprises 10-15% of all lung cancer cases. In this webinar for patients and caregivers, Matthew Hellmann, M.D., of Memorial Sloan Kettering Cancer Center discusses the new FDA approval, clinical trials, and potential treatments for patients with small cell lung cancer.
Watch Now

Spotlight

Discover how Futurism AI is revolutionizing the healthcare industry with cutting-edge AI and Machine Learning technologies. Delve into how we leverage AI to predict and prevent equipment failures, monitor disease outbreaks, expedite clinical trials, detect fraudulent activity, and pioneer drug development.

resources